Disease-modifying therapy during pregnancy and postpartum relapse activity in women with multiple sclerosis undergoing assisted reproductive technology treatment: a nationwide cohort study
Relapse activity was more than two times higher 3 months postpartum than before and during pregnancy. Stratified for DMT exposure during pregnancy, rate ratios were similar and did not reach statistical significance. Postpartum relapse activity more than doubled from both low ARR (unexposed to DMT during pregnancy) and higher ARR (exposed to DMT during pregnancy) pre-pregnancy.
Authors
- Melinda Magyari (ORCID: https://orcid.org/0000-0002-0972-5222)
- Lene Mia von Kappelgaard (ORCID: https://orcid.org/0000-0002-3670-6457)
- Elisabeth Framke (ORCID: https://orcid.org/0000-0002-5702-3954)
- Juan-Enrique Schwarze (ORCID: https://orcid.org/0000-0001-8988-521X)
- Ditte Vassard (ORCID: https://orcid.org/0000-0001-6298-4146)
- Anja Pinborg (ORCID: https://orcid.org/0000-0002-8340-104X)
- Meritxell Sabidó (ORCID: https://orcid.org/0000-0002-4281-6759)
Institutions
- University of Copenhagen (DK)
- Merck KGaA, Darmstadt (Germany) (DE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Multiple Sclerosis Center (DK)
Publication Details
- Journal
- BMJ Neurology Open
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1136/bmjno-2025-001092
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Biogen
- Scleroseforeningen
- Merck KGaA
- Multiple Sclerosis Society